Genovis releases its Annual Report for 2006

Genovis is releasing its Annual Report for 2006 today on the company’s website at
www.genovis.com Printed copies of the report can be requested from the company by
telephone at (+46) (0) 46-101230.

Significant events during 2006

• A new share issue for about SEK 10 million was carried out in March for the purpose of
financing the shift from research and development to production. The new share issue was
oversubscribed by around 90 percent.

• Product launch: The Genovis NIMT™ Nanoheater and consumable NIMT™ FeOdots
were launched at the BioTech/ScanLab trade fair in Copenhagen. The applications have
relevance to three different business areas: gene transfer, RNA interference and magnetic
labeling of cells.

• Change of market for the company’s Class B shares. Genovis moved from the Öresund
List/Nordic OTC to First North, which is a part of the Nordic OMX stock exchange.

• A research group from the NIH, National Institutes of Health, Maryland, USA, has used
Genovis products, NIMT™ FeOdots, in order to track treated stem cells inside an animal
model using MRI.
• A preferential rights issue for SEK 20.3 million was carried out in December in order to
maintain the pace of commercial development and to finance production. The preferential
rights issue was oversubscribed by about 99 percent.

Sarah Fredriksson
CEO, Genovis AB